Recent News

• 08.14.2025 - Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
• 07.24.2025 - Applied DNA Announces New Follow-On LineaDNA™ Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
• 07.07.2025 - Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
• 06.30.2025 - Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
• 06.17.2025 - Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
• 06.16.2025 - Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
• 05.29.2025 - Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
• 05.29.2025 - Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
• 05.15.2025 - Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

Recent Filings

• 07.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 07.07.2025 - 8-K Current report
• 06.30.2025 - EX-99.1 EX-99.1
• 06.30.2025 - 8-K Current report
• 06.17.2025 - 8-K Current report
• 06.17.2025 - EX-99.1 EX-99.1
• 06.06.2025 - 8-K Current report
• 05.29.2025 - 8-K Current report
• 05.29.2025 - EX-99.1 EX-99.1
• 05.22.2025 - 8-K Current report